Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. [electronic resource]
Producer: 20120316Description: 6521-8 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Antigens, CD -- metabolism
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Dasatinib
- Drug Administration Schedule
- Female
- Flow Cytometry
- Fusion Proteins, bcr-abl -- genetics
- Gene Expression Regulation, Leukemic -- drug effects
- Humans
- Immunophenotyping
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Multivariate Analysis
- Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
- Protein Kinase Inhibitors -- therapeutic use
- Pyrimidines -- administration & dosage
- Recurrence
- Remission Induction
- Reverse Transcriptase Polymerase Chain Reaction
- Steroids -- administration & dosage
- Thiazoles -- administration & dosage
- Time Factors
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.